For oncology trials, liquid biopsy technology holds great promise. Applications include screening patients for trial enrollment, monitoring the success of therapy, and diagnosing disease recurrence. Beyond clinical trials, as the technology advances, it could be used to find cancers in their most nascent stages and inform prognoses.
Liquid biopsy involves analyzing blood or other bodily fluids, such as urine, saliva, or cervical fluid, for genetic information that provides indications of disease state. In cancer, the most frequently used sources of this information are circulating tumor cells and circulating tumor DNA (ctDNA).